The median time since SM diagnosis was longer for responders than for all patients (34.5 vs 25.9 months), and presence of the KIT D816V mutation at any time was more common in responders (100 %) compared with the total ASM population (78.4 %). This evidence concerns the gene KIT and systemic mastocytosis.